이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

초경 이후의 생식축 성숙

초경 이후의 생식축 성숙: 파일럿 연구

Background:

Most adult women with irregular periods of unknown cause report symptoms dating back to early adolescence. This study aims to learn how girls' periods change in the 2 years after their first period. We are also looking at girls who may have a condition called PCOS. This will help researchers learn what healthy puberty looks like and how they can spot signs of hormone problems early on.

Objective:

To learn how long it takes girls to develop regular menstrual cycles after their first period.

Eligibility:

Healthy girls ages 8-14 who either (1) haven't had their first period but show signs of puberty, such as breast development and hair in the genital area; or (2) had their first period in the past 6 months

Girls at risk for PCOS age 8-14 who have a mom or sister with PCOS

Girls with irregular menstrual cycles age 11-17.5

To compare with the girls, we are looking at women >=18-34 years old with PCOS,

Healthy women >= 18-34 years old without PCOS,

and Mothers of pediatric participants age 18-65

Design:

Both parents or guardians must allow their daughter to participate. They must attend all study visits with her.

Participants will first be screened by phone. Those who qualify will be screened in person. They will have a physical exam. They will give blood and urine samples. They will have an ultrasound of their abdomen. They will fill out questionnaires. They will sit in a BOD POD for 6 minutes: This is an egg- shaped machine that takes body measurements. They have the option to provide DNA samples.

Participants will have sets of visits at home or at the clinic about every 6 months. The number of visits in each set will depend on their menstrual cycle. Then they will have a final visit. Visits will include repeats of the screening tests. There are additional parts that participants may choose to be involved in depending on how involved they want to be.

At home, participants will collect their urine daily to measure hormones. They will keep a diary of their periods.

Adults: Women with known PCOS will complete the same Screening Visit as the girls and will collect dried urine specimens at home for 8 weeks;

The Healthy control women group will complete the same Screening Visit as the girls and collect dried urine specimens at home for 2 menstrual cycles;

The Mothers of pediatric participants group will complete a Screening Visit (informed consent, urine pregnancy test) and collect vaginal swab specimens at home for 2 menstrual cycles (approx. 8 weeks).

연구 개요

상세 설명

The broad goal of these studies is to determine the physiologic and pathophysiologic underpinnings of irregular menstrual cycles among adolescents in general and those with increased genetic risk for polycystic ovarian syndrome (PCOS) in the early postmenarchal

period. Irregular menstruation affects > 2.5 million reproductive-age women in the US each year1. Most adult women with oligomenorrhea of unknown etiology reporting symptoms dating back to early adolescence. Importantly, irregular menstrual cycles during the teenage years may be a harbinger of future health risks extending beyond the reproductive system; among the nearly 80,000 female participants the Nurses' Health Study II, those with irregular and long cycles during adolescence and adulthood had a greater risk of premature mortality, particularly related to cardiovascular disease. While a period of cycle irregularity is well-described in the first few years after menarche, a lack of understanding of the basic mechanisms of normal reproductive axis development in the post-menarchal female has hampered our ability to distinguish abnormal from normal developmental trajectories. Moreover, the commonly held belief that menstrual irregularity among teenage girls is normal has also delayed detection of pathology in reproductive development, precluding institution of early preventative strategies to curtail future reproductive morbidity.

연구 유형

관찰

등록 (추정된)

400

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

  • 이름: NIEHS Join A Study Recruitment Group
  • 전화번호: (855) 696-4347
  • 이메일: myniehs@nih.gov

연구 연락처 백업

연구 장소

    • North Carolina
      • Research Triangle Park, North Carolina, 미국, 27709
        • 모병
        • NIEHS Clinical Research Unit (CRU)
        • 연락하다:
          • NIEHS Join A Study Recruitment Group
          • 전화번호: 855-696-4347
          • 이메일: myniehs@nih.gov

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

8년 (어린이, 성인, 고령자)

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

여성

샘플링 방법

비확률 샘플

연구 인구

Healthy early post-menarchal girls age 8-<15 years; PCOS women and girls with first degree relatives with PCOS; Healthy women 18-34 years; Late post-menarchal girls age 11-<17.5; healthy pre-menarchal girls age 8-<14.5; mothers of pediatric participants age 18-65

설명

  • Part 1 - Pre-menarche monitoring ("holding pattern"):

Inclusion Criteria:

  • Age 8-14.5 years old
  • Healthy weight, defined as having a body weight >85% of expected (EBW) and a body mass index (BMI) <99th percentile
  • Some breast development
  • Pre-menarche

Exclusion Criteria:

  • Taking or planning to take medications that affect reproductive hormones in the next 2 to 3 years (e.g. birth control pills, biotin supplements).
  • Planning to move more than 60 miles from the CRU within the next 2 to 3 years
  • Chronic medical condition, including but not limited to diabetes mellitus, congenital adrenal hyperplasia, cystic fibrosis, sickle cell disease, inflammatory bowel disease, juvenile rheumatoid arthritis, and lupus.
  • First-degree relative with polycystic ovarian syndrome, premature ovarian insufficiency, hypogonadotropic hypogonadism, or other pubertal development disorder
  • Excessive exercise (defined as running >20 miles per week or its equivalent)
  • Pregnancy

Part 2 - Post-menarche cycle tracking:

Inclusion Criteria:

  • Age at menarche 10-14.5 years old
  • Healthy weight, defined as having a body weight >85% of expected (EBW) and a body mass index (BMI) <99th percentile
  • Approximately < 6 months post-menarchal (will typically have completed 4 or fewer menstrual cycles)
  • Biochemical criteria: normal thyroid hormone, prolactin, and testosterone levels

Exclusion Criteria:

  • Taking or planning to take medications that affect reproductive hormones in the next 2 to 3 years (e.g. birth control pills, biotin supplements).

  • Planning to move more than 60 miles from the CRU within the next 2 to 3 years

  • Chronic medical condition, including but not limited to diabetes mellitus, congenital adrenal hyperplasia, cystic fibrosis, sickle cell disease, inflammatory bowel disease, juvenile rheumatoid arthritis, and lupus.

  • First-degree relative with polycystic ovarian syndrome, premature ovarian insufficiency, hypogonadotropic hypogonadism, or other pubertal development disorder

  • Excessive exercise (defined as running >20 miles per week or its equivalent)

  • Anemia (defined as hemoglobin <12.0 g/dl)

    --Participants with hemoglobin between 11.5 g/dl and 12.0 g/dl may still participate by providing dried blood spots, or no more than 18 ml of blood during any given interval.

  • Pregnancy

Part 3 - Intensive monitoring of ovarian follicle growth

Inclusion Criteria:

  • Age at menarche 10-14.5 years old
  • Healthy weight, defined as having a body weight >85% of expected (EBW) and a body mass index (BMI) <99th percentile
  • Within 1 year of menarche
  • Biochemical criteria: normal thyroid hormone, prolactin, and testosterone levels

Exclusion Criteria:

  • Taking or planning to take medications that affect reproductive hormones in the next 1-2 years (e.g. birth control pills, biotin supplements).

  • Planning to move more than 60 miles from the CRU within the next year

  • Chronic medical condition, including but not limited to diabetes mellitus, congenital adrenal hyperplasia, cystic fibrosis, sickle cell disease, inflammatory bowel disease, juvenile rheumatoid arthritis, and lupus.

  • First-degree relative with polycystic ovarian syndrome, premature ovarian insufficiency, hypogonadotropic hypogonadism, or other pubertal development disorder

  • Excessive exercise (defined as running >20 miles per week or its equivalent)

  • Anemia (defined as hemoglobin <12.0 g/dl)

    --Participants with hemoglobin between 11.5 g/dl and 12.0 g/dl may still participate by providing dried blood spots, or no more than 18 ml of blood during any given interval.

  • Pregnancy

Part 4 - Late Post-menarche cycle tracking:

Inclusion Criteria:

  • Age 11-17.5 years old
  • Approximately 2-5 years post-menarchal
  • Biochemical criteria: normal thyroid hormone and prolactin

Exclusion Criteria:

  • Taking or planning to take medications that affect reproductive hormones in the next 2 to 3 years (e.g. birth control pills, biotin supplements).

  • Planning to move more than 60 miles from the CRU within the next 6 months

  • Chronic medical condition, including but not limited to diabetes mellitus, congenital adrenal hyperplasia, cystic fibrosis, sickle cell disease, inflammatory bowel disease, juvenile rheumatoid arthritis, and lupus.

  • Anemia (defined as hemoglobin <12.0 g/dl)

    --Participants with hemoglobin between 11.5 g/dl and 12.0 g/dl may still participate by providing dried blood spots, or no more than 18 ml of blood during any given interval.

  • Pregnancy

Adolescent girls, at-risk daughters, or sisters of women with PCOS

The girls with mothers or sisters with PCOS group will complete the Screening Visit and Parts 1-3. The same inclusion and exclusion criteria apply for Parts 1, 2, and 3 as stated above except that these individuals must have a first-degree relative with PCOS and they can have high androgen levels, excess body hair, and severe acne at screening.

Women with known PCOS (activities for 8 weeks only)

Inclusion Criteria:

  • Age >=18-34 years old
  • PCOS diagnosis
  • at least 3-years post-menarchal with irregular menstrual cycles
  • Biochemical (blood) or clinical signs of high androgen levels

Exclusion Criteria:

  • Cannot be taking any medications that affect reproductive or metabolic hormones (e.g. birth control pill, biotin supplements, spironolactone, metformin).
  • Chronic medical condition, including but not limited to diabetes mellitus, congenital adrenal hyperplasia, cystic fibrosis, sickle cell disease, inflammatory bowel disease, juvenile rheumatoid arthritis, and lupus.
  • Pregnancy

Healthy control women (Activities for 2 menstrual cycles)

Inclusion Criteria:

  • Age >=18-34 years old
  • at least 3-years post-menarchal with regular menstrual cycles every 21-35 days

Exclusion Criteria:

  • Cannot be taking any medications that affect reproductive or metabolic hormones (e.g. birth control pill, biotin supplements, spironolactone, metformin).
  • Chronic medical condition, including but not limited to diabetes mellitus, congenital adrenal hyperplasia, cystic fibrosis, sickle cell disease, inflammatory bowel disease, juvenile rheumatoid arthritis, and lupus.
  • PCOS diagnosis or first-degree relative with disorder
  • Pregnancy

Mothers of pediatric participants (Activities for 8 weeks / 2 menstrual cycles)

Inclusion Criteria:

  • Age >=18-65 years old
  • Biological mother of A Girl's First Period participant

Exclusion Criteria:

  • Chronic medical condition, including but not limited to diabetes mellitus, congenital adrenal hyperplasia, cystic fibrosis, sickle cell disease, inflammatory bowel disease, juvenile rheumatoid arthritis, and lupus.
  • Pregnancy

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: COHORT
  • 시간 관점: PROSPECTIVE

코호트 및 개입

그룹/코호트
At-risk girls

Girls with first degree relative diagnosed with Polycystic Ovary Syndrome (PCOS) age 8-<15

early post-menarche girls

Healthy, early post-menarchal girls age 8-<15

Healthy control women

Women age >18-34 without PCOS at least 3-years post-menarchal with regular menstrual cycles every 21-35 days

late post-menarche girls

Late post-menarchal girls age 11-<17.5 (gynecological age 2-5)

Mothers of pediatric study participants

Mothers age 18-65 whose daughter has provided at least one vaginal swab sample for the First Period study.

pre-menarche girls

Healthy, pre-menarchal girls age 8-<14.5

Women with PCOS

Women diagnosed with PCOS >18-34 at least 3-years post-menarchal with irregular menstrual cycles

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
To determine the time from menarche to regular ovulatory cycles, defined as two consecutive ovulatory cycles in girls of variable genetic risk for PCOS
기간: Defined as two consecutive ovulatory cycles with normal (10-14 day) luteal phase length during the first two post-menarchal years

We hypothesize that the temporal sequence of reproductive maturation will consist of anovulatory cycles (representing a time of unopposed estrogen exposure), ovulatory cycles with a short luteal phase (estrogen with low progesterone exposure), and finally, ovulatory cycles with a normal luteal phase length (estrogen action fully counterbalanced by progesterone action)

Defined as two consecutive ovulatory cycles with normal (10-14 day) luteal phase length during the first two post-menarchal years

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Natalie D Shaw, M.D., National Institute of Environmental Health Sciences (NIEHS)

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2019년 12월 19일

기본 완료 (추정된)

2029년 7월 1일

연구 완료 (추정된)

2029년 7월 1일

연구 등록 날짜

최초 제출

2019년 6월 13일

QC 기준을 충족하는 최초 제출

2019년 6월 13일

처음 게시됨 (실제)

2019년 6월 14일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 5일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 4일

마지막으로 확인됨

2026년 11월 3일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 190110
  • 19-E-0110

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

미정

IPD 계획 설명

It is not yet known if there will be a plan to make IPD available

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다